[68Ga]Ga-PentixaFor positron emission tomography for improved risk and disease assessment in myeloma
Key facts
- Where
- Edegem, Gent és Leuven, BelgiumSee the 3 sites
- Phase
- 1/2. fázis
Where in Belgium
- Antwerp University HospitalEdegem, BelgiumTaking people
- Universitair Ziekenhuis GentGent, BelgiumTaking people
- UZ LeuvenLeuven, BelgiumTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Of Antwerp
- Trial code
- EU 2022-501811-14-00
- Record updated
- 2026. szeptember 2.
- Original description
To evaluate the proportion of false negative (FN) PET results for [68Ga]Ga-PentixaFor PET/AC-CT at baseline.Read full original descriptionShow less
To evaluate the proportion of false negative (FN) PET results for [68Ga]Ga-PentixaFor PET/AC-CT at baseline.
Inclusion: Transplant-eligible newly diagnosed multiple myeloma based on current IMWG criteria and scheduled for induction chemotherapy followed by ASCT; Baseline 18F-FDG PET/CT scan; WHO performance status 0-2 (WHO > 2 can be allowed if the patient is fit for intensive chemotherapy based on the opinion of the physician); 18 years of older; Signed informed consent; Life expectancy > 12 months, based on clinical judgement; Baseline [68Ga]Ga-PentixaFor PET/CT should be scheduled before starting induction chemotherapy; An interval of maximum 14 days is allowed between the 18F-FDG and [68Ga]Ga-PentixaFor PET/CT scans (Specific for this study).
Exclusion: History of concomitant presence of any other malignancy, except for: non-melanoma skin cancer, carcinoma in situ of the cervix, or any other effectively treated malignancy that has been in remission for >5 years or that is highly likely to be cured at the time of enrollment; Any physical or physiological condition that may affect adherence to the study protocol, e.g severe claustrophobia or the inability to lie still for 30 minutes; Pregnant or breastfeeding; Refusal or inability to provide written informed consent.